C12orf63 Inhibitors
Chemical inhibitors of C12orf63 can interact with and impede the protein's function through various mechanisms, primarily by targeting the enzymes and kinases that regulate the cell cycle, a process with which C12orf63 is associated. Alsterpaullone, Roscovitine, Olomoucine, Indirubin-3'-monoxime, Purvalanol A, Flavopiridol, PD0332991, Dinaciclib, Milciclib, Ribociclib, and Abemaciclib are all chemical inhibitors that act on cyclin-dependent kinases (CDKs), which are pivotal in cell cycle control. Alsterpaullone and Roscovitine, for example, inhibit CDKs to prevent the phosphorylation of downstream targets necessary for cell cycle progression, thereby inhibiting the role of C12orf63 in this process. Olomoucine serves a similar function, targeting CDKs to impede cell cycle progression and thus the function of C12orf63. Indirubin-3'-monoxime goes further by inhibiting not just CDKs but also GSK-3beta, affecting both cell division and signaling pathways that could involve C12orf63.
Flavopiridol and Purvalanol A are potent inhibitors that halt cell cycle progression through their action on CDKs, thus affecting the role of C12orf63 in regulating or promoting cell cycle-related events. PD0332991, also known as Palbociclib, specifically inhibits CDK4 and CDK6 leading to an arrest in the G1 phase of the cell cycle, which would directly affect C12orf63 function if it is essential for the progression past this checkpoint. Dinaciclib offers a broader range of inhibition, affecting multiple CDKs crucial for cell cycle regulation and potentially impacting processes that involve C12orf63. Milciclib targets multiple CDKs and potentially other kinases, impacting not just the cell cycle but potentially other pathways wherein C12orf63 operates. Lastly, Ribociclib and Abemaciclib selectively inhibit CDK4 and CDK6, causing a G1 phase arrest, and thereby would impact C12orf63 if it plays a role during this cell cycle phase. Each chemical, through its inhibition of CDKs and related kinases, can disrupt the normal function of C12orf63 by impeding the cell cycle progression and signaling pathways the protein is involved in.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is known to inhibit cyclin-dependent kinases (CDKs). Since C12orf63 is involved in cell cycle control, the inhibition of CDKs by Alsterpaullone would prevent the phosphorylation of downstream targets required for cell cycle progression, which C12orf63 is a part of. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs which are essential for cell cycle progression. By inhibiting these kinases, Roscovitine prevents the cell from properly transitioning through the cell cycle phases, thereby inhibiting the function of proteins like C12orf63 that are involved in this process. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor which would impair the cell cycle, thereby inhibiting C12orf63's role in cell cycle regulation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a potent inhibitor of CDKs and GSK-3beta, affecting cell division and signaling. Inhibition of these kinases indirectly inhibits C12orf63 by disrupting the signaling pathways and cell cycle mechanisms it is involved with. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
As a potent inhibitor of CDKs, Purvalanol A disrupts cell cycle progression. This disruption would inhibit the function of C12orf63 if it is involved in regulating or promoting cell cycle-related events. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
A potent inhibitor of adenosine kinase, 5-Iodotubercidin disrupts adenosine metabolism which can impact multiple signaling pathways. By disrupting these pathways, it indirectly inhibits C12orf63 function if the protein operates within these pathways. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol strongly inhibits CDKs, leading to a halt in cell cycle progression. This inhibits C12orf63 by preventing the progression through cell cycle phases where C12orf63 may play a role. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Also known as Palbociclib, this chemical inhibits CDK4 and CDK6, leading to cell cycle arrest in the G1 phase. This directly inhibits the function of C12orf63 if it is essential for cell cycle progression past this checkpoint. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib inhibits multiple CDKs, including CDK2, CDK5, CDK1, and CDK9, which are crucial for cell cycle regulation. This broad inhibition disrupts cellular processes that C12orf63 is potentially involved in. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib targets multiple CDKs and may inhibit other kinases, impacting the cell cycle and other pathways. This would functionally inhibit C12orf63 by preventing the progression of cell cycle phases that C12orf63 may regulate. | ||||||